ORPHA:319322
Mucinous tubular and spindle cell renal carcinoma
Publications
101
46.2th percentile
Trials
0
Interventional, condition-specific
Researchers
556
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Mucinous tubular and spindle cell renal carcinoma is a rare subtype of renal cell carcinoma characterized, histologically, by tubular architecture and sheets of spindle cells embedded in a mucinous/myxoid stroma and, macroscopically, by a solid, generally well-circumscribed, partially encapsulated tumor of variable size, with a homogenously colored, bulging cut surface, occassionally containing areas of hemorrhage or necrosis, usually located in the cortex. Patients can present abdominal/flank pain, adbominal mass and/or hematuria, however most are asymptomatic and tumor is discovered incidentally. Indolent behavior is frequent and association with nephrolithiasis and end-stage kidney disease has been noted.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0003011
- UMLS:C4707257
- NCIT:C39807
Additional Mondo synonyms (3)
carcinoma, renal, tubular, malignant · mucinous tubular and spindle cell carcinoma of the kidney · mucinous tubular and spindle cell renal carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
101 matched papers (44 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 48 for broader category renal carcinoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
101
101 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
101 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
44 in the last 10 years · high confidence · 46.2th percentile (publications denominator)
Phrase hits: 101 · MeSH hits: 0
Who's working on it?
556
Distinct author names in 101 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Nagashima Y4 papers · 2021
Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.
Papers in Europe PMC - 02Argani P3 papers · 2017
Department of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Papers in Europe PMC - 03Ayala AG3 papers · 2018
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030.
Papers in Europe PMC - 04Chen YB3 papers · 2019
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.
Papers in Europe PMC - 05Huang J3 papers · 2022
Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
Papers in Europe PMC - 06Reuter VE3 papers · 2018Papers in Europe PMC
- 07Ro JY3 papers · 2018
Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX 77030. Electronic address: jaero@houstonmethodist.org.
Papers in Europe PMC - 08Wang H3 papers · 2025
Department of Pathology, The Third Affiliated Hospital of Soochow University 185 Juqian Street, Changzhou 213003, P. R. China.
Papers in Europe PMC - 09Wang L3 papers · 2022
Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, PR China.
Papers in Europe PMC - 10Zhang S3 papers · 2014Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 48 trials are registered for renal carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
48 interventional trials matched renal carcinoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: renal carcinoma
48
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07092566·RECRUITING·R.E.C.K vs Exparel in Robotic Nephrectomy
Conditions: Renal Carcinoma · Nephrectomy / Methods · Pain Management·Matched via name phrase
- NCT07028125·RECRUITING·Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
Conditions: Renal Cell Carcinoma (Kidney Cancer) · Metastatic Renal Cell Carcinoma · Locally Advanced·Matched via name phrase
- NCT07716917·NOT YET RECRUITING·Genitourinary Tumors With Sacituzumab Tirumotecan
Conditions: Papillary Renal Carcinoma · Variant Histology Urothelial Carcinoma·Matched via name phrase
- NCT06940518·RECRUITING·Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Conditions: Ivonescimab · Clear Cell Renal Carcinoma·Matched via name phrase
- NCT06290427·RECRUITING·Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K)
Conditions: Renal Carcinoma·Matched via name phrase
- NCT07046832·ENROLLING BY INVITATION·Clinical Evaluation of an Augmented Reality Intraprocedural Needle Guidance Platform for Soft Tissue Biopsy
Conditions: Oncology · Interventional Radiology · Liver Carcinoma · Renal Carcinoma·Matched via name phrase
- NCT05665361·RECRUITING·Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
Conditions: Advanced Clear Cell Renal Carcinoma (Ccrcc) · Papillary Renal Cell Carcinoma (Prcc)·Matched via name phrase
- NCT03786796·RECRUITING·Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Conditions: Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Kidney Cancer · Renal Carcinoma·Matched via name phrase
- NCT07397611·RECRUITING·Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Conditions: Renal Cell Carcinoma · Kidney Cancer · Kidney Neoplasm · Renal Carcinoma·Matched via name phrase
- NCT06959433·NOT YET RECRUITING·Lu-177 PSMA Treatment in Cell Renal Carcinoma
Conditions: Metastatic Renal Cancer·Matched via name phrase
- NCT07517198·RECRUITING·Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Conditions: Solid Tumor · Small Cell Lung Cancer (SCLC) · High Grade Neuroendocrine Cancer · Small Cell Carcinomas of Non-lung Origin·Matched via name phrase
- NCT07043608·RECRUITING·Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases
Conditions: Clear Cell Renal Cell Cancer (ccRCC) · Clear Cell Renal Carcinoma · Clear Cell Renal Cell Carcinoma Metastatic · Clear Cell Renal Cancer·Matched via name phrase
- NCT07566897·NOT YET RECRUITING·A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Conditions: Renal Carcinoma Metastatic · Pancreatic Adenocarcinoma Metastatic · Pancreatic Adenocarcinoma · Metastatic Colorectal Carcinoma (mCRC)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 61 · after dedupe 61 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 61 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (61)
- isrctn·ISRCTN10760016·No longer recruiting·A study of the drugs AZD2014 and rituximab in relapsed or refractory diffuse large B-cell lymphoma
skipped — LLM skipped (--skip-llm)
- ctis·2026-526116-36-00·Authorised·A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy
skipped — LLM skipped (--skip-llm)
- ctis·2026-526821-16-00·Authorised·Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma
skipped — LLM skipped (--skip-llm)
- ctis·2025-522757-19-00·Authorised·A Cancer Research UK Phase II trial of CY-101 given via intratumoural administration in locally advanced or metastatic adrenocortical carcinoma (CLARITY)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523994-41-00·Authorised·A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523067-38-01·Authorised·Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
skipped — LLM skipped (--skip-llm)
- ctis·2025-523617-29-01·Authorised·Tolerability and efficacy of treating locally advanced Resectable Oral Cancer with neoadjuvant INtratumoral anti-CTLA4 ImmunoTherapy combined with systemic anti-PD-1 (ROCinIT).
skipped — LLM skipped (--skip-llm)
- ctis·2025-523482-23-00·Authorised·PITALC. Pilot study on the effect of PITAC (Pressurized IntraThoracic Aerosol Chemotherapy) by videothoracoscopy in patients with malignant pleural effusion in the light of the results of a retrospective historical cohort treated with talc pleurodesis by videothoracoscopy
skipped — LLM skipped (--skip-llm)
- ctis·2025-524403-80-00·Authorised·A Phase 3, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants with Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
skipped — LLM skipped (--skip-llm)
- ctis·2024-519985-35-00·Authorised·Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy: a phase II trial
(OBLUMEN)
skipped — LLM skipped (--skip-llm)
- ctis·2025-523633-25-00·Authorised·A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT
skipped — LLM skipped (--skip-llm)
- ctis·2025-524139-38-00·Authorised·A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease
skipped — LLM skipped (--skip-llm)
- ctis·2026-525808-94-00·Authorised·EXUROC Bladder Target - A phase Ib/ll study to determine the safety, tolerability, and efficacy of LP-184 treatment in patients with advanced/metastatic urothelial carcinoma
skipped — LLM skipped (--skip-llm)
- ctis·2025-523923-22-00·Authorised·A Phase 2, Open-Label, Single-Arm Study of Lirafugratinib in Patients With Previously Treated, Unresectable, Locally Advanced or Metastatic Solid Tumors (Excluding Cholangiocarcinoma) With FGFR2 Fusion or Rearrangement
skipped — LLM skipped (--skip-llm)
- ctis·2025-524285-18-00·Authorised·A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
skipped — LLM skipped (--skip-llm)
- ctis·2024-510793-24-00·Authorised·Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I
skipped — LLM skipped (--skip-llm)
- ctis·2026-525844-14-00·Authorised·Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants with End-Stage Kidney Disease on Hemodialysis
skipped — LLM skipped (--skip-llm)
- ctis·2026-526388-39-00·Authorised·Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial - The CALCIFER Trial
skipped — LLM skipped (--skip-llm)
- ctis·2024-517799-40-00·Authorised·A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024
skipped — LLM skipped (--skip-llm)
- ctis·2023-507214-28-00·Authorised·Network pharmacology-based personalized drug repurposing in thyroid carcinoma: a pilot feasibility trial
skipped — LLM skipped (--skip-llm)
- ctis·2025-524623-50-00·Authorised·A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
skipped — LLM skipped (--skip-llm)
- ctis·2025-524299-44-00·Authorised·First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor
skipped — LLM skipped (--skip-llm)
- ctis·2025-525009-18-00·Authorised·A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
skipped — LLM skipped (--skip-llm)
- ctis·2026-526113-28-00·Authorised·Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
skipped — LLM skipped (--skip-llm)
- ctis·2025-524312-11-00·Authorised·Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Mucinous tubular and spindle cell renal carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mucinous tubular and spindle cell renal carcinoma" OR "carcinoma, renal, tubular, malignant" OR "mucinous tubular and spindle cell carcinoma of the kidney" OR "mucinous tubular and spindle cell carcinoma of kidney"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mucinous tubular and spindle cell renal carcinoma" OR "carcinoma, renal, tubular, malignant" OR "mucinous tubular and spindle cell carcinoma of the kidney" OR "mucinous tubular and spindle cell carcinoma of kidney"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"renal carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:26:02.550Z
